USANA Health Sciences, Inc. - 10-K Summary (Fiscal Year Ended Jan 2, 2010)
Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 2, 2010 (52-week year).
Business Model: USANA develops, manufactures, and distributes science-based nutritional and personal care products through a global network marketing system. The customer base consists of independent "Associates" (distributors) and "Preferred Customers" (personal use only). As of January 2, 2010, the company had 199,000 active Associates and 67,000 active Preferred Customers across 14 markets.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 | Change |
|---|---|---|---|
| Net Sales | $436.9 million | $429.0 million | +1.8% |
| Gross Profit | $347.1 million | $340.1 million | +2.1% |
| Gross Margin | 79.4% | 79.3% | +0.1% |
| Net Earnings | $33.6 million | $29.9 million | +12.1% |
| Diluted EPS | $2.17 | $1.85 | +$0.32 |
| Operating Cash Flow | $32.5 million | $46.0 million | -29.3% |
| Cash & Equivalents | $13.7 million | $13.3 million | +$0.4 million |
| Line of Credit Balance | $7.0 million | $35.0 million | -$28.0 million |
| Total Assets | $123.4 million | $122.6 million | +$0.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by $7.9 million. Growth was driven by an increase in active Associates and the addition of the Philippines market (generating $6.5 million in sales). This was partially offset by a strengthening U.S. dollar, which reduced reported net sales by approximately $17 million, and a decline in active Preferred Customers.
- Profitability: Net earnings increased 12.1% to $33.6 million. This improvement was primarily due to a significant decrease in Selling, General, and Administrative (SG&A) expenses compared to 2008, which included a one-time $7.0 million arbitration award. Excluding the 2008 arbitration award, net earnings would have decreased slightly due to currency headwinds and higher Associate incentive costs.
- Expense Ratios: Associate incentives increased to 44.9% of net sales (from 41.6% in 2008) due to the full-year impact of Compensation Plan enhancements introduced in late 2008. SG&A expenses decreased to 22.9% of net sales (from 26.5% in 2008) as the one-time arbitration award and related legal fees were not present in 2009.
- Geographic Performance: North America sales declined 7.7% due to economic conditions and currency fluctuations. Conversely, Asia Pacific sales grew 20.9%, driven by strong growth in East Asia (Hong Kong, Taiwan) and Southeast Asia.
Outlook, Risks, and Management Commentary
- Management Strategy: Management plans to focus on reducing operating costs, improving operating margins, and optimizing raw material sourcing in 2010. The company intends to continue investing in the "Matching Bonus" program to drive sales productivity.
- Product Updates: In Q3 2009, the company reformulated flagship products (Essentials and HealthPak) and increased prices in the U.S. by approximately 6% and 3%, respectively, to improve gross margins.
- Key Risks:
- Currency Fluctuation: With 65.3% of sales generated outside the U.S., a strengthening U.S. dollar negatively impacts reported sales and earnings.
- Associate Dependence: The business relies entirely on independent Associates for sales. High turnover or failure to attract new Associates could materially harm results.
- Regulatory Environment: The company faces scrutiny from the FTC and FDA regarding advertising claims and network marketing regulations. Changes in laws could restrict operations or require compensation plan modifications.
- Competition: Intense competition from larger network marketing companies (e.g., Amway, Herbalife) for both consumers and distributors.
- Liquidity: The company maintains a $40 million line of credit with Bank of America, with $7 million outstanding as of year-end. Management believes cash flows and credit facilities are sufficient for foreseeable needs.
Investor Verification Checklist
- Associate Retention: Verify the trend in active Associates, particularly in North America where numbers declined by 9.3% in 2009.
- Currency Impact: Monitor the U.S. dollar strength relative to key markets (Canada, Australia, Asia) as it significantly impacts reported revenue.
- Incentive Costs: Track the Associate incentive expense ratio (currently 44.9%) to ensure it does not erode margins further as the company scales.
- Legal Proceedings: Review the status of the Chirco vs. USANA class action lawsuit filed in Nevada regarding pyramid scheme allegations.
- Debt Covenants: Confirm continued compliance with the line of credit covenants, specifically the adjusted EBITDA requirement of $50 million.